AbbVie pulls the trigger on a Covid-19 antibody, going all in on a drug discovered by research alliance

Nicole DeFeudis

Editor

With multiple repurposed Covid-19 treatments already in the clinic (and one that flunked out), AbbVie is placing its next bet on something new: an experimental …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie pulls the trigger on a Covid-19 antibody, going all in on a drug discovered by research alliance

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists ...

Biotech VC firm outlines plans for $100M fund

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Gilead's Kite uncouples from Fosun in China as Yescarta faces coverage obstacles

Breaking down silos with a new quantitative approach to drug development

Ab­b­Vie pulls the trig­ger on a Covid-19 an­ti­body, go­ing all in on a drug dis­cov­ered by re­search al­liance

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AbbVie pulls the trigger on a Covid-19 antibody, going all in on a drug discovered by research alliance